Form 4: CFO Spiro Sakiris Granted 30,500 Restricted Shares

Intelligent Bio Solutions CFO Spiro Sakiris received 30,500 restricted common stock shares under the 2019 Long Term Incentive Plan, subject to vesting conditions.

Summary

• Chief Financial Officer Spiro Kevin Sakiris was granted a total of 30,500 restricted shares of Intelligent Bio Solutions Inc. common stock on March 18, 2026.
• This includes 9,150 restricted shares subject to time-based vesting after 48 months.
• An additional 21,350 restricted shares were granted, subject to joint performance-based and time-based vesting requirements.
• All awarded shares are subject to forfeiture until vested.
• The company previously effected a 1-for-10 reverse stock split on December 15, 2025, and all share amounts in this filing are presented on a post-split basis.
• Following these transactions, Mr. Sakiris directly beneficially owns 33,981 shares and indirectly owns 1,911 shares through Anest Holdings Pty Ltd.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine executive compensation event, slightly positive as it aligns management incentives with long-term shareholder value through vesting conditions, but it does not provide new operational or financial performance data.

Positives

• Granting of restricted stock aligns management incentives with long-term shareholder value through vesting conditions.
• The awards are part of the existing 2019 Long Term Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The shares are restricted and subject to forfeiture, meaning the CFO does not have immediate full ownership.

Risks

• Restricted shares are subject to forfeiture if vesting conditions (time-based and performance-based) are not met.

Future Outlook

The filing indicates future vesting events for the restricted shares, with time-based vesting occurring after 48 months for one portion and joint performance-based and time-based vesting for another portion.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through restricted stock grants with vesting conditions, is a common practice across industries to align management interests with long-term company performance and shareholder value. The use of a long-term incentive plan is standard for publicly traded companies.

Comparison to Industry Standards

• The grant of restricted stock to a Chief Financial Officer is a standard compensation practice, comparable to similar grants at companies like Bio-Rad Laboratories (BIO) or Thermo Fisher Scientific (TMO) for their executives, which often include a mix of time-based and performance-based vesting to incentivize long-term value creation.
• The 48-month vesting period for a portion of the shares is within typical industry ranges for long-term incentive plans, often seen in tech and biotech sectors to retain key talent.
• The inclusion of performance-based vesting aligns with best practices in corporate governance, linking executive rewards directly to company achievements, similar to structures at companies like Pfizer (PFE) or Johnson & Johnson (JNJ).

Related Party Transactions

• Indirect beneficial ownership of 1,911 shares through Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, where Mr. Sakiris is a director.

Stakeholder Impact

• Shareholders: Potential long-term benefit from aligned management incentives; dilution from new share issuance is minimal in the context of total outstanding shares.
• Employees: No direct impact on general employees, but reflects the company's executive compensation strategy.

Next Steps

• Vesting of 9,150 restricted shares after 48 months from March 18, 2026.
• Vesting of 21,350 restricted shares based on joint performance-based and time-based requirements.

Key Dates

Recommendation

This Form 4 filing details a routine restricted stock grant to the CFO, which is a standard executive compensation practice. While it aligns management incentives with long-term shareholder value, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a "hold" recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

Intelligent Bio Solutions, INBS, Form 4, Restricted Stock, Stock Grant, CFO, Executive Compensation, Long Term Incentive Plan, Reverse Stock Split